Welcome to our dedicated page for COGNITION THERAPEUTICS news (Ticker: CGTX), a resource for investors and traders seeking the latest updates and insights on COGNITION THERAPEUTICS stock.
Cognition Therapeutics, Inc. develops clinical-stage drug candidates for neurodegenerative disorders, with news centered on zervimesine (CT1812), an investigational oral small molecule designed to protect neuronal synapses from toxic protein oligomers. Company updates commonly address dementia with Lewy bodies, Alzheimer’s disease, mild cognitive impairment, and geographic atrophy secondary to dry AMD.
Recurring developments include Phase 2 study data from programs such as SHIMMER and START, regulatory interactions with U.S. and European agencies, scientific conference presentations, expanded access activity, and quarterly financial results. News also covers NIH-related grant funding, cash runway commentary, and clinical-development plans tied to zervimesine’s use across central nervous system and retina indications.
Cognition Therapeutics (NASDAQ: CGTX) released the eighth episode of its Conversations video podcast titled “Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease.” This episode explores how beta amyloid (Aβ) oligomers lead to synaptic dysfunction and cognitive decline. The podcast discusses recent research showing Aβ oligomers binding to synapses in Alzheimer's patients and how CT1812 can reverse this binding and reduce toxicity. Highlights include the use of quantitative EEG as a biomarker in the Phase 2 ‘SEQUEL’ study, which showed improvements in synaptic function and brain connectivity after four weeks of CT1812 treatment. Dr. Hamby presented proteomic analysis results demonstrating CT1812's positive effects on proteins and pathways linked to Alzheimer's. The discussion was moderated by Dr. Anthony Caggiano, featuring Dr. Mary Hamby, Dr. Everard Vijverberg, and Dr. Tara Spires-Jones.
Cognition Therapeutics, Inc. (Nasdaq: CGTX) reported financial results for Q1 2024 and provided business updates. They completed enrollment of 130 participants in the SHIMMER study for Alzheimer's and DLB, with topline results expected mid-2024. The company also raised $11.9 million in a public offering and presented research findings at conferences.
Financially, the company has $34.7 million in cash and $62.3 million in grant funds. Research and development expenses increased to $10.6 million, leading to a net loss of $9.2 million for the quarter.
Cognition Therapeutics, Inc. completed enrollment in the Phase 2 SHIMMER study of CT1812 for mild-to-moderate dementia with Lewy bodies. Top-line results are expected in the second half of 2024. The study aims to develop a disease-modifying therapy for DLB by targeting Aβ and α-synuclein oligomers.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.